One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

NCT01139021 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
508
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Vaccines